Alpha Cognition Reports Strong Q3 2026 Growth Driven by ZUNVEYL Sales
Alpha Cognition (ACOG) reported significant commercial momentum in its third quarter of 2026, highlighted by a 230% year-over-year increase in net product revenue to $7.8 million. This growth was primarily driven by the accelerating volume of ZUNVEYL prescriptions and improved prescriber productivity, with filled prescriptions rising 40% sequentially to 11,000. The company demonstrated strong operational efficiency, maintaining a 94% GAAP gross product margin while narrowing its operating loss due to revenue growth outpacing flat operating expenses. Despite an inconclusive pharmacokinetic study for the sublingual format of ZUNVEYL, management remains optimistic following extended patent protection through 2045 and positive data from the CONVERGE study.
Topics: financial guidance operating loss product adoption revenue growth